Retrotope is developing a pipeline of proprietary therapeutics designed to treat degenerative disease by down-regulating LPO in order to protect against cellular degeneration.
At Retrotope, we are pioneering the development of first-in-class therapies for devastating degenerative diseases - ranging from orphan neurodegenerative indications to large market degenerative conditions - for which there are few to no treatment options.
We are leveraging our proprietary drug discovery platform technology, along with our dedicated team of scientific leaders and industry veterans, to create novel, disease-modifying therapies designed to combat the oxidative stress and cellular degeneration that arise from lipid peroxidation.
|Compound||Indication||Discovery/Preclinical||Phase I||Phase II||Phase III|
Stabilized Linoleic Acid (LA,
Infantile neuroaxonal dystrophy (INAD)
Friedreich's ataxia (FA)
Amyotrophic lateral sclerosis (ALS)
Progressive supranuclear palsy (PSP)
acid (DHA, ethyl ester)
|Dry Age-Related Macular Degeneration (Dry AMD) and geographic atrophy (GA)|
|Other stabilized PUFAs||Huntington’s disease (HD), Spinocerebellar ataxia (SCA) and Multiple system atropy (MSA)|
Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases, today announced that Anil Kumar, president and chief business officer, will deliver a corporate...
Welcome to the 2nd Annual Dry AMD Therapeutic Development Summit: Uncovering the Largest Untapped Eyecare Market
The Only End-to-End Forum Solely Dedicated to Targeting Inflammatory/Regenerative Pathways Whilst Overcoming Challenges With Drug Delivery, Safety and Validated Endpoints To Bring About Clinically Effective Dry-AMD Therapies
Founder and CSO; Director
Senior VP, Ophthalmology